PC
ASMB icon

PA Capital’s Assembly Biosciences ASMB Stock Holding History

PA Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-960
Closed -$155K – 123
2019
Q2 		$155K Sell
960
-518
-35% -$98.5K 0.14% 99
2019
Q1 		$349K Buy
1,478
+225
+18% +$57K 0.31% 83
2018
Q4 		$340K Buy
+1,253
New +$362K 0.36% 78

Other funds holding ASMB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PA Capital's ASMB Position: Q3 2019 in Review

PA Capital sold out of Assembly Biosciences (ASMB) in Q3 2019, closing a stake of 960 shares — an estimated $155K sold.

PA Capital first reported a position in ASMB in Q4 2018 and held it in 3 quarters. The position peaked at $349K in Q1 2019. 98 funds tracked by Wall St. Rank hold ASMB as of Q3 2019.

  • PA Capital reported no remaining Assembly Biosciences position as of Q3 2019 after selling out during the quarter.
  • PA Capital sold 960 Assembly Biosciences shares in Q3 2019, an estimated $155K.
  • PA Capital first reported a position in Assembly Biosciences in Q4 2018 and held it in 3 quarters.
  • PA Capital's Assembly Biosciences position peaked at $349K in Q1 2019.
  • 98 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2019.

Based on PA Capital's 13F filing for Q3 2019, filed 8 Nov 2019.